Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 30, 2025 21:47 ET | Source: RO

Best Wegovy Pricing for 2026: Industry Analysis of FDA-Approved Oral and Injectable Cost Pathways as Telehealth Access Expands

Industry analysis compares FDA-approved Wegovy pricing from $149 oral to Ro's $199 injectable as telehealth access expands for 2026.
December 29, 2025 21:19 ET | Source: LeanRx, Inc.

Best Zepbound Alternative for 2026? FDA Regulatory Timeline Reshapes Telehealth Tirzepatide Access as SkinnyRx Platform Lists Compounded Options

Industry analysis examines FDA tirzepatide compounding timeline and telehealth access pathways as SkinnyRx lists options starting at $299/month.
December 29, 2025 18:14 ET | Source: MEDVI

Best Weight Loss Pills for 2026? FDA Approves First Oral GLP-1 as Patients Evaluate Wegovy, Zepbound, and Telehealth Access Pathways

FDA approves first oral GLP-1 for weight loss as patients evaluate Wegovy, Zepbound, and compounded options. MEDVi lists programs from $179.
December 26, 2025 23:34 ET | Source: Direct Meds

Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts

Analysis examines Direct Meds GLP-1 medications platform as LegitScript-certified telehealth option for compounded semaglutide and tirzepatide access.
June 10, 2025 19:26 ET | Source: Mochi Health

Mochi Health Launches Enhanced Online Platform to Support Medical Weight Loss Patients Nationwide

SAN FRANCISCO, June 10, 2025 (GLOBE NEWSWIRE) -- Mochi Health, a physician-founded telehealth company delivering medical weight loss care directly to patients, announced today the launch of its...
April 25, 2025 17:48 ET | Source: TMates

TMates Under Review: Affordable GLP-1 Medication Website to Buy Semaglutide, Tirzepatide, Phentermine & More

New York City, April 25, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: Why traditional weight loss methods often fail due to metabolic resistance, hormonal imbalances, and emotional...
May 21, 2024 08:30 ET | Source: Mangoceuticals, Inc.

MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications

Formulations to be marketed as “Slim” and “Trim” as an Oral Dissolvable Tablet (ODT) Dallas, TX, May 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”),...